Sofosbuvir is a potent nucleotide HCV NS5B polymerase inhibitor that is also a P-glycoprotein (encoded by the ABCB1 gene) and breast cancer resistance protein (encoded by the ABCG2 gene) substrate. Concerning previous anti-HCV therapies, pharmacogenetics had a significant impact, particularly considering the association of interleukin28B polymorphisms with dual-therapy (ribavirin + pegylated IFN) outcomes.

Pharmacogenetics of the anti-HCV drug sofosbuvir: a preliminary study

Cusato, Jessica;De Nicolò, Amedeo;Boglione, Lucio;Favata, Fabio;Ariaudo, Alessandra;Mornese Pinna, Simone;Carcieri, Chiara;Avataneo, Valeria;Di Perri, Giovanni;D'Avolio, Antonio
2018

Abstract

Sofosbuvir is a potent nucleotide HCV NS5B polymerase inhibitor that is also a P-glycoprotein (encoded by the ABCB1 gene) and breast cancer resistance protein (encoded by the ABCG2 gene) substrate. Concerning previous anti-HCV therapies, pharmacogenetics had a significant impact, particularly considering the association of interleukin28B polymorphisms with dual-therapy (ribavirin + pegylated IFN) outcomes.
73
6
1659
1664
Cusato, Jessica; De Nicolò, Amedeo; Boglione, Lucio; Favata, Fabio; Ariaudo, Alessandra; Mornese Pinna, Simone; Carcieri, Chiara; Guido, Federica; Avataneo, Valeria; Cariti, Giuseppe; Di Perri, Giovanni; D'Avolio, Antonio
File in questo prodotto:
File Dimensione Formato  
dky053.pdf

non disponibili

Tipo di file: PDF EDITORIALE
Dimensione 359.13 kB
Formato Adobe PDF
359.13 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/1678724
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 6
social impact